Darolutamide before surgery for AR-positive triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a drug called darolutamide, alone or with standard chemotherapy, before surgery for a type of breast cancer that is triple-negative but has a high level of the androgen receptor (AR). It is for people with stage II or IIIA breast cancer that can be removed surgically.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a new diagnosis of triple-negative breast cancer that tests positive for the androgen receptor (AR).
- Your tumor must be at least 1 cm in size or be stage II to IIIA and planned for treatment before surgery.
- You must have adequate kidney, liver, and blood cell function as shown by blood tests.
- You must not be pregnant or breastfeeding and agree to use contraception during and for 120 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
This study tests whether giving the drug darolutamide (with or without standard hormone therapy) before surgery helps shrink high-risk prostate cancer and reduce the chance of it coming back. If you qualify, you would receive the study treatment for a few months before your planned prostate removal surgery.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This trial tests a new way of using darolutamide (a hormone therapy) together with standard chemotherapy (docetaxel) and hormone therapy (ADT) for men with prostate cancer that has spread. The goal is to see if taking darolutamide on an intermittent schedule works as well as continuous treatment.
This study tests a triple treatment (darolutamide, hormone therapy, and chemotherapy) for men whose prostate cancer has spread and still responds to hormone therapy. The goal is to see if this combination works better than standard care in controlling the cancer and improving outcomes.
Hear when a new Anatomic Stage II Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.